Pulmonary vasculitis care focuses on a group of conditions in which inflammation affects the blood vessels of the lungs, potentially disrupting oxygen delivery and causing tissue injury. The disease may occur as a primary lung disorder or as part of systemic autoimmune conditions such as granulomatosis with polyangiitis, eosinophilic granulomatosis, or connective tissue diseases. Patients can present with a variety of symptoms, including persistent cough, shortness of breath, coughing up blood, fever, fatigue, and, in some cases, involvement of other organs such as the kidneys. Because the manifestations can mimic infections or other lung diseases, early recognition is critical to prevent severe complications such as respiratory failure, pulmonary hemorrhage, or permanent lung damage. Accurate diagnosis requires careful evaluation using blood tests for inflammatory markers, imaging studies including high-resolution CT scans, and, when needed, tissue biopsy to confirm vessel inflammation while excluding infectious or malignant causes.
The management of pulmonary vasculitis emphasizes reducing inflammation, protecting lung function, and preventing recurrence. Immunosuppressive medications, including corticosteroids and targeted agents such as cyclophosphamide or rituximab, are often central to treatment. Supportive strategies such as oxygen therapy, monitoring for infections, and careful follow-up are also critical. Pulmonary vasculitis care benefits greatly from a multidisciplinary approach, involving pulmonologists, rheumatologists, and critical care specialists to tailor therapy for each patient. Long-term management includes regular assessment of lung function, adjustment of immunosuppressive therapy, and prompt intervention for disease flare-ups. Advances in molecular and immunologic research are enabling more precise diagnosis and individualized treatment plans, improving outcomes and quality of life for patients living with pulmonary vasculitis.
Title : Screening questionnaires for obstructive sleep apnea: An updated systematic review
Behzad Rahmati, Isfahan University of Medical Sciences, Iran (Islamic Republic of)
Title : Improving covid 19 candidate vaccine response through probiotics and micronutrient supplementation: Evaluating the role of TLR5
Zohre Eftekhari, Biotechnology Research Center, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Novel signaling mechanisms and innovative therapeutic strategies of pulmonary hypertension
Yong Xiao Wang, Albany Medical College, United States
Title : Iatrogenic pneumothorax following nephrectomy: Case report
Chaimae Tahiri, National University Hospital Center of Fann, Senegal